1. A novel bacteriophage \u03a6CJ22 (KCCM11364P) having a specific bactericidal activity against Clostridium perfringens.
2. A composition for preventing or treating an infectious disease caused by Clostridium perfringens, comprising the bacteriophage \u03a6CJ22 (KCCM11364P) of claim 1 as an active ingredient.
3. The composition according to claim 2, wherein the infectious disease is necrotic enteritis.
4. An antibiotic comprising the bacteriophage \u03a6CJ22 (KCCM11364P) of claim 1 as an active ingredient.
5. A feed additive or drinking water additive comprising the bacteriophage \u03a6CJ22 (KCCM11364P) of claim 1 as an active ingredient.
6. A disinfectant or cleaner comprising the bacteriophage \u03a6CJ22 (KCCM11364P) of claim 1 as an active ingredient.
7. A method of preventing or treating an infectious disease caused by Clostridium perfringens, comprising administering the bacteriophage \u03a6CJ22 (KCCM11364P) of claim 1.
8. The method according to claim 7, wherein the infectious disease is necrotic enteritis.
9. A method of preventing or treating an infectious disease caused by Clostridium perfringens, comprising administering the the composition of claim 2 to animals except for humans.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1-36. (canceled)
37. A composition comprising nebivolol or a pharmaceutically acceptable salt thereof, and an angiotensin II receptor antagonist (ARB) selected from the group consisting of olmesartan, valsartan, losartan, and combinations thereof, and pharmaceutically acceptable salts thereof.
38. The composition of claim 37, wherein the ARB is selected from the group consisting of losartan, valsartan, and combinations thereof, and pharmaceutically acceptable salts thereof.
39. The composition of claim 37, wherein the ARB is losartan or a pharmaceutically acceptable salt thereof.
40. A method of treating or preventing hypertension in a patient in need thereof, comprising administering to said patient an effective amount of nebivolol or a pharmaceutically acceptable salt thereof, and an angiotensin II receptor antagonist (ARB) selected from the group consisting of olmesartan, valsartan, losartan, and combinations thereof, and pharmaceutically acceptable salts thereof.
41. The method of claim 40, wherein the ARB is selected from the group consisting of losartan, valsartan, and combinations thereof, and pharmaceutically acceptable salts thereof.
42. The method of claim 40, wherein the ARB is losartan or a pharmaceutically acceptable salt thereof.
43. A method of treating or preventing cardiovascular disease in a patient in need thereof, comprising administering to said patient an effective amount of nebivolol or a pharmaceutically acceptable salt thereof, and an angiotensin II receptor antagonist (ARB) selected from the group consisting of olmesartan, valsartan, losartan, and combinations thereof, and pharmaceutically acceptable salts thereof.
44. The method of claim 43, wherein the ARB is selected from the group consisting of losartan, valsartan, and combinations thereof, and pharmaceutically acceptable salts thereof.
45. The method of claim 43, wherein the ARB is losartan or a pharmaceutically acceptable salt thereof.